Current Report Filing (8-k)
March 20 2019 - 6:16AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities and Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 16, 2019
Gene
Biotherapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-33635
|
|
27-0075787
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
11568
Sorrento Valley Rd., Suite 14
|
|
|
San
Diego, California
|
|
92121
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 436-1000
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Potential
persons who are to respond to the collection of information contained in this form are not required to respond unless the form
displays a currently valid OMB control number.
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS:
On
March 16, 2019, Gerald J. Lewis (age 85) retired as a member of the Registrant’s Board of Directors (“Board”).
Mr. Lewis was initially elected to the Board in 2006 and has continuously served on the Board for the past 14 years.
During.
Mr. Lewis’ years of distinguished service the Company successfully (1) acquired Innercool Therapies, secured FDA clearance
for the RapidBlue™ endovascular therapeutic hypothermia system, built a 30,000 square foot cGMP manufacturing facility in
San Diego, before selling the business to Royal Philips, the Dutch conglomerate, (2) initiated clinical studies and secured FDA
510(k) clearance for the Excellagen® advanced dermal matrix, which was subsequently sold to Olaragen Therapeutix, and (3)
acquired the Generx® [Ad5FGF-4] angiogenic gene therapy product candidate from Schering AG (now Bayer AG) for the treatment
of patients with myocardial ischemia and refractory angina, which has received FDA-clearance and Fast-Track designation to advance
forward into a new U.S.-based Phase 3 clinical study.
Item
9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
Gene
Biotherapeutics, Inc.
|
|
|
|
By:
|
/s/
Christopher J. Reinhard
|
|
|
Christopher J. Reinhard
|
|
|
Chief Executive Officer
|
|
Date:
March 20, 2019
Taxus Cardium Pharmaceut... (CE) (USOTC:CRXM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Taxus Cardium Pharmaceut... (CE) (USOTC:CRXM)
Historical Stock Chart
From Apr 2023 to Apr 2024